Blackburnwinkler5824
To investigate the influence of treatment regularity with intravitreal aflibercept injections (IVT-AFL injections) on visual acuity (VA) outcomes in patients with neovascular age-related macular degeneration (nAMD) enrolled in the PERSEUS trial who received at least 7 IVT-AFL injections during the first year.
This was a post hoc analysis of the PERSEUS trial, a prospective, non-interventional, multicenter cohort study, and included 370 patients with nAMD who had received ≥ 7 IVT-AFL injections during year 1. In addition to the prespecified subgroups of treatment-naïve and previously treated patients, results were compared between patients with regular (n = 209) and irregular (n = 161) treatment. Regular treatment was defined as initial dosing with monthly IVT-AFL injections for 3months, then bimonthly IVT-AFL injections until month 12. Irregular treatment was defined as any deviation from regular treatment (provided ≥ 7 injections were received). The outcome of primary interest was the mean change in VA fof injections was significantly higher in the irregular than in the regular sub-cohort (8.0 ± 1.2 vs. 7.4 ± 0.6; P = 0.0001). Furthermore, compared with the treatment-naïve, regular sub-cohort, patients in the irregular sub-cohort had more visits (19.1 ± 8.6 vs. 16.1 ± 5.7), VA tests (14.2 ± 6.9 vs. 12.0 ± 4.6), and optical coherence tomography examinations (5.1 ± 3.7 vs. 3.4.0 ± 3.0).
Although irregularly treated patients received more injections and more monitoring visits during the first year of IVT-AFL treatment, they experienced worse VA outcomes than regularly treated patients.
Although irregularly treated patients received more injections and more monitoring visits during the first year of IVT-AFL treatment, they experienced worse VA outcomes than regularly treated patients.
To study the diagnostic potential of retro-mode scanning laser ophthalmoscopy (RM-SLO) for evaluation of peripheral retinal lesions.
Based on the results of indirect ophthalmoscopy, in this study, we included asymptomatic subjects with lattice retinal degeneration, retinal break, or subclinical retinal detachment and subjects without any peripheral retinal lesions. All participants' fundus periphery was examined with RM-SLO over 360° for the presence of peripheral retinal lesions in a masked fashion. Detection rate for retinal breaks and detachments were compared between indirect ophthalmoscopy and RM-SLO.
Twenty-six subjects (52 eyes, 15 males and 11 females, 34.8 ± 11.8 years) were included in the peripheral retinal lesion group and 25 individuals (50 eyes, 10 males and 15 females, 42.8 ± 14.5 years) were included in the group without peripheral retinal lesions. GNE-049 Among the patients with peripheral retinal lesions detected with indirect ophthalmoscopy in at least one eye, RM-SLO categorized 20.7% (p = 0.031) more eyes as having subclinical asymptomatic retinal detachment or at least one retinal break. Additionally, RM-SLO demonstrated 55.0% (p = 0.001) more subclinical retinal detachments and 31.5% (p = 0.002) more asymptomatic retinal breaks.
RM-SLO showed high potential in diagnosing peripheral retinal lesions and may be a useful additional diagnostic tool for the patients who demonstrate peripheral retinal lesions with indirect ophthalmoscopy.
RM-SLO showed high potential in diagnosing peripheral retinal lesions and may be a useful additional diagnostic tool for the patients who demonstrate peripheral retinal lesions with indirect ophthalmoscopy.
We investigated the ability of baseline 2-deoxy-2-[
F]fluoro-D-glucose PET/CT parameters, acquired before the start of immunotherapy, to predict development of hyperprogressive disease (HPD) in melanoma patients. We also evaluated the diagnostic performances of ratios of baseline and first restaging PET/CT parameters to diagnose HPD without information of the tumor growth kinetic ratio (TGKR) that requires pre-baseline imaging before baseline imaging (3 timepoint imaging).
Seventy-six patients who underwent PET/CT before and approximately 3months following initiation of immunotherapy were included. PET/CT parameters, including metabolic tumor volume (MTV) for all melanoma lesions and total measured tumor burden (TMTB) based on irRECIST, were measured from baseline PET/CT (MTV
and TMTB
) and first restaging PET/CT (MTV
and TMTB
). The ratios of MTV (MTV
/MTV
, MTVr) and TMTB (TMTB
/TMTB
, TMTBr) were calculated.
MTV
of HPD patients (n = 9, TGKR ≥ 2) was larger than that of non-HPD (n = 67, TGKR < 2) patients (P <0.05), and HPD patients demonstrated shorter median overall survival (7 vs. more than 60months, P <0.05). The area under the curve (AUC) of MTV
(≥ 155.5ml) to predict the risk of HPD was 0.703, with a sensitivity of 66.7% and specificity of 81.2%. The AUCs of MTVr (≥ 1.25) and TMTBr (≥ 1.27) to diagnose HPD without information of TGKR were 0.875 and 0.977 with both sensitivities of 100%, and specificities of 79% and 83.9%, respectively.
Patients at high risk of developing HPD could not be accurately identified based on baseline PET/CT parameters. The ratios of baseline and first restaging PET/CT parameters may be helpful to diagnose HPD, when patients do not undergo pre-baseline imaging.
Patients at high risk of developing HPD could not be accurately identified based on baseline PET/CT parameters. The ratios of baseline and first restaging PET/CT parameters may be helpful to diagnose HPD, when patients do not undergo pre-baseline imaging.
Oral squamous cell carcinoma (OSCC) has not seen a substantial improvement in patient survival despite therapeutic advances, making accurate detection and characterization of the disease a clinical priority. Here, we aim to demonstrate the effectiveness of magnetic resonance imaging (MRI) with the targeted MRI contrast agent MT218 specific to extradomain-B fibronectin (EDB-FN) in the tumor microenvironment for detection and characterization of aggressive OSCC tumors.
EDB-FN expression was evaluated in human normal tongue and OSCC specimens with immunohistochemistry. Invasiveness of human CAL27, HSC3, and SCC4 OSCC cells was analyzed with spheroid formation and transwell assays. EDB-FN expression in the cells was analyzed with semiquantitative real-time PCR, western blotting, and a peptide binding study with confocal microscopy. Contrast-enhanced MRI with MT218 was performed on subcutaneous OSCC mouse models at a dose of 0.04mmol/kg, using gadoteridol (0.1mmol/kg) as a control.
Strong EDB-FN expression was observed in human untreated primary and metastatic OSCC, reduced expression in treated OSCC, and little expression in normal tongue tissue.
